Literature DB >> 32446654

Roles of CDK/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expression.

Pascal Loyer1, Janeen H Trembley2.   

Abstract

Cyclin Dependent Kinases (CDKs) represent a large family of serine/threonine protein kinases that become active upon binding to a Cyclin regulatory partner. CDK/cyclin complexes recently identified, as well as "canonical" CDK/Cyclin complexes regulating cell cycle, are implicated in the regulation of gene expression via the phosphorylation of key components of the transcription and pre-mRNA processing machineries. In this review, we summarize the role of CDK/cyclin-dependent phosphorylation in the regulation of transcription and RNA splicing and highlight recent findings that indicate the involvement of CDK11/cyclin L complexes at the cross-roads of cell cycle, transcription and RNA splicing. Finally, we discuss the potential of CDK11 and Cyclins L as therapeutic targets in cancer.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CCNL1; CCNL2; CDK11; Cell Cycle; Cyclin L; Transcription; cancer; pre-mRNA splicing

Year:  2020        PMID: 32446654     DOI: 10.1016/j.semcdb.2020.04.016

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  7 in total

1.  Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold.

Authors:  Zhengnian Li; Ryosuke Ishida; Yan Liu; Jinhua Wang; Yina Li; Yang Gao; Jie Jiang; Jianwei Che; Jason M Sheltzer; Matthew B Robers; Tinghu Zhang; Kenneth D Westover; Behnam Nabet; Nathanael S Gray
Journal:  Eur J Med Chem       Date:  2022-05-08       Impact factor: 7.088

2.  CONSTITUTIVE EXPRESSER OF PATHOGENESIS-RELATED GENES 5 is an RNA-binding protein controlling plant immunity via an RNA processing complex.

Authors:  Shun Peng; Dongbei Guo; Yuan Guo; Heyu Zhao; Jun Mei; Yakun Han; Rui Guan; Tianhua Wang; Teng Song; Keke Sun; Yunhan Liu; Ting Mao; Huan Chang; Jingshi Xue; Yingfan Cai; Dong Chen; Shui Wang
Journal:  Plant Cell       Date:  2022-04-26       Impact factor: 12.085

3.  Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells.

Authors:  Lei Zhang; Biwei Ye; Yunfeng Lin; Yi-Dong Li; Jing-Quan Wang; Zhuo Chen; Feng-Feng Ping; Zhe-Sheng Chen
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.988

4.  CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.

Authors:  Lei Zhang; Yidong Li; Chaohua Hu; Yangmin Chen; Zhuo Chen; Zhe-Sheng Chen; Jian-Ye Zhang; Shuo Fang
Journal:  Mol Cancer       Date:  2022-04-22       Impact factor: 41.444

5.  Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome.

Authors:  Phoebe C R Parrish; James D Thomas; Austin M Gabel; Shriya Kamlapurkar; Robert K Bradley; Alice H Berger
Journal:  Cell Rep       Date:  2021-08-31       Impact factor: 9.423

6.  The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages.

Authors:  Keiko Taniguchi-Ponciano; Lesly A Portocarrero-Ortiz; Gerardo Guinto; Sergio Moreno-Jimenez; Erick Gomez-Apo; Laura Chavez-Macias; Eduardo Peña-Martínez; Gloria Silva-Román; Sandra Vela-Patiño; Jesús Ordoñez-García; Sergio Andonegui-Elguera; Aldo Ferreira-Hermosillo; Claudia Ramirez-Renteria; Etual Espinosa-Cardenas; Ernesto Sosa; Ana Laura Espinosa-de-Los-Monteros; Latife Salame-Khouri; Carolina Perez; Blas Lopez-Felix; Guadalupe Vargas-Ortega; Baldomero Gonzalez-Virla; Marcos Lisbona-Buzali; Daniel Marrero-Rodríguez; Moisés Mercado
Journal:  BMC Med Genomics       Date:  2022-03-08       Impact factor: 3.063

Review 7.  Protein kinase CK2 - diverse roles in cancer cell biology and therapeutic promise.

Authors:  Janeen H Trembley; Betsy T Kren; Muhammad Afzal; George A Scaria; Mark A Klein; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2022-09-17       Impact factor: 3.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.